Phase 3 Trial Confirms Ibrance Plus Hormone Therapy Benefits ER+ Breast Cancer Patients
News
The CDK4/6 inhibitor Ibrance (palbociclib), when added to hormone therapy normally given to certain advanced breast cancer patients, considerably benefits these people, researchers at the University of California, Los Angeles (UCLA), reported in an ... Read more